Positron Emission Tomography Shows Reduced Striatal Dopamine D1 but not D2 Receptors in Juvenile Neuronal Ceroid Lipofuscinosis

Abstract

We studied striatal dopamine D1 and D2 receptors in patients with juvenile neuronal ceroid lipofuscinosis (JNCL) with positron emission tomography (PET) using a dopamine D1 receptor antagonist [¹¹C]NNC 756 and a dopamine D2 receptor antagonist [¹¹C]raclopride as ligands.

The mean [¹¹C]NNC 756 uptake value in JNCL was reduced by 15 % from the mean control value in the putamen (p < 0.01) and by 13 % in the caudate nucleus (p < 0.01). The mean [¹¹C]raclopride uptake in JNCL patients was not significantly different from the mean of the control group either in the putamen or the caudate nucleus. Our results show a mild reduction in striatal dopamine D1 but not in D2 receptors in JNCL, indicating slightly impaired striatal neuronal function. The contribution of these changes to the extrapyramidal symptoms of the patients and their treatment deserves further studies.

D1, D2, Dopamine - JNCL - Neuronal Ceroid Lipofuscinosis - PET, Positron Emission Tomography - Receptors

References

• 1 Abi-Dargham A, Simpson N, Kegeles L. et al . PET studies of binding competition between endogenous dopamine and the D1 radiotracer [¹¹C]NNC 756.  Synapse. 1999;  32 93-109
• 2 Autti T, Raininko R, Santavuori P, Vanhanen S L, Poutanen V P, Haltia M. MRI of neuronal ceroid lipofuscinosis. II. Postmortem MRI and histopathological study of the brain in 16 cases of neuronal ceroid lipofuscinosis of juvenile or late infantile type.  Neuroradiology. 1997;  39 371-377
• 3 Autti T, Raininko R, Vanhanen S L, Santavuori P. MRI of neuronal ceroid lipofuscinosis, I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis.  Neuroradiology. 1996;  38 476-482
• 4 Dewey S L, Smith G S, Logan J, Brodie J D, Fowler J S, Wolf A P. Striatal binding of the PET ligand by [¹¹C]raclopride is altered by drugs that modify synaptic dopamine levels.  Synapse. 1993;  13 350-356
• 5 DeVolder A G, Cirelli S, De Barsy Th, Brucher J M, Bol A, Michel Ch, Goffinet A M. Neuronal ceroid-lipofuscinosis: preferential metabolic alterations in thalamus and posterior association cortex demonstrated by PET.  J Neurol Neurosurg Psychiatry. 1990;  53 1063-1067
• 6 Flaherty A W, Graybiel A M. Anatomy of the basal ganglia. Marsden CD, Fahn S Movement Disorders 3. Cambridge, UK; Butterworth-Heinemann 1994: 3-27
• 7 Gardiner R M, Sanford A, Deadman M. et al . Batten disease (Spielmeyer-Vogt; juvenile onset neuronal ceroid lipofuscinosis) maps to human chromosome 16.  Genomics. 1990;  8 387-390
• 8 Halldin C, Farde L, Högberg T. et al . A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding.  Nucl Med Biol. 1991;  18 871-881
• 9 Hofman I, Kohlschütter A, Santavuori P. et al . CLN3, Juvenile NCL. Goebel HH, Mole SE, Lake BD The Neuronal Ceroid Lipofuscinoses (Batten Disease). Amsterdam; IOS Press 1999: 55-76
• 10 Kemppainen N, Ruottinen H, Någen K, Rinne J O. PET shows that dopamine D1 and D2 receptors are differentially affected in AD.  Neurology. 2000;  55 205-209
• 11 Lachowicz J, Sibley D. Molecular characteristics of mammalian dopamine receptors.  Pharmacol Toxicol. 1997;  81 105-113
• 12 Laihinen A O, Rinne J O, Ruottinen H M. et al . PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756.  J Nuclear Med. 1994;  35 1916-1920
• 13 Logan J, Fowler J S, Volkow N D, Wang G J, Ding Y S, Alexoff D L. Distribution volume ratios without blood sampling from graphical analysis of PET data.  J Cereb Blood Flow Metab. 1996;  16 834-840
• 14 Missale C, Nash Robinson S S, Jaber M, Caron M. Dopamine receptors: from structure to function.  Physiol Rev. 1998;  78 189-225
• 15 Någren K, Müller L, Halldin C, Swahn C-G, Lehikoinen L. Improved synthesis of some commonly used PET radioligands by the use of [¹¹C]methyl triflate.  Nuclear Med Biol. 1995;  22 235-239
• 16 Philippart M, Messa C, Chugani H T. Spielmeyer-Vogt (Batten, Spielmeyer-Sjögren) disease. Distinctive patterns of cerebral glucose utilization.  Brain. 1994;  117 1085-1092
• 17 Rinne J O, Hietala J, Ruotsalainen U. et al . Decrease in human striatal dopamine D₂ receptor density with age: a PET study with [¹¹C]raclopride.  J Cereb Blood Flow Metab. 1993;  13 310-314
• 18 Ruottinen H M, Rinne J O, Haaparanta M, Solin O, Bergman J, Oikonen V, Järvelä I, Santavuori P. [¹⁸F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.  J Neurol Neurosurg Psychiatry. 1997;  62 622-625
• 19 Santavuori P. Neuronal ceroid lipofuscinoses in childhood.  Brain Dev. 1988;  10 80-83
• 20 Santavuori P, Rapola J, Sainio K, Raitta Ch. A variant of Jansky-Bielschowsky disease.  Neuropediatrics. 1982;  13 135-141
• 21 Seeman P, Guan H C, Niznik H B. Endogenous dopamine lowers the dopamine receptor density as measured by [³H]raclopride: implications for positron emission tomography of the human brain.  Synapse. 1989;  3 96-97
• 22 Young L T, Wong D F, Goldman S. et al . Effects of endogenous dopamine on kinetics of [³H]N-methylspiperone and by [³H]raclopride binding in the rat brain.  Synapse. 1991;  9 188-194
• 23 Zeman W, Donohue S, Dyken P, Green J. The neuronal ceroid-lipofuscinoses (Batten-Vogt syndrome). Vinken P, Bruyn GW Handbook of Clinical Neurology. Vol. X. Amsterdam; North Holland 1970: 588-679
• 24 Åberg L, Liewendahl K, Nikkinen P, Autti T, Rinne J O, Santavuori P. Decreased striatal dopamine transporter density in JNCL patients with Parkinsonian symptoms.  Neurology. 2000;  54 1069-1074
• 25 Åberg L E, Rinne J O, Rajantie I, Santavuori P. A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis.  Neurology. 2001;  56 1236-1239